Lab-made toad compound nasal spray shows rapid antidepressant effects in phase 2b trial A single dose of a nasal spray containing synthetic mebufotenin, a compound inspired by the Sonoran desert toad, significantly reduced depressive symptoms in patients with treatment-resistant depression, with effects lasting up to eight weeks. A single dose of a nasal spray containing a lab-made version of a psychedelic compound found in desert toads significantly reduced symptoms of treatment-resistant depression, according to a phase 2b clinical trial. The drug, mebufotenin benzoate, also known as 5-MeO-DMT, is being developed by AtaiBeckley, which is owned by Eli Lilly. The trial included 193 adults aged 18 to 75 from the United States, Europe, and Australia. All participants had treatment-resistant depression and had already tried at least two antidepressant treatments without success. They were randomly assigned to receive a low, medium, or high dose of the nasal spray.Mebufenotin Benzoate Doses And ResultsThe medium dose was 8 milligrams and the high dose was 12 milligrams, while the low dose was 0.3 milligrams. Both the 8 mg and 12 mg doses helped over 34% of participants. The 8 mg dose saw the most improvement, with a 12 point reduction in depression scores on a 60-point scale after four weeks. The 12 mg group dropped an average of 11.1 points, while the 0.3 mg group dropped 5.5 points.A quarter of those on the 8 mg dose saw a remission of their depression after a single treatment, meaning symptoms fell below the threshold for qualifying depression. The therapeutic effects appeared as early as two days after treatment and held through the end of the eight-week study. Most patients were able to leave the clinic within two hours.Among those who received the 8 milligram dose, 85 percent were ready for discharge within two hours, compared with 78 percent of those who received the 12 milligram dose. In contrast, psilocybin can last over six hours. Side effects were common, with 76% of patients receiving the 8 mg dose and 85% receiving the 12 mg dose reporting adverse events. Nearly all reported events, 99.7%, were classified as mild or moderate.The nasal spray was developed by biotech firm AtaiBeckley. Its active ingredient, mebufotenin, is synthetic and made in a lab. It is based on a compound found in the glands of the Sonoran desert toad. For decades, amateur psychonauts have sought out these toads for the prominent glands on their head and hind legs.Squeezing those glands releases a milky secretion, sometimes inaccurately called venom, which when dried and vaporized produces an intense psychedelic experience. Many people who have smoked it describe a profound sense of oneness or ego dissolution, and some even report the sensation of dying. The nasal spray aims to deliver therapeutic benefits without the need for an all-day mystical trip. The researchers wanted to see if a controlled, clinical dose could provide rapid relief while keeping treatment brief.Nasal Spray Provides Rapid And Robust ReliefThe study authors wrote: In adults with treatment-resistant depression, single doses of intranasal mebufotenin benzoate were well tolerated and produced rapid, robust, and durable reductions in depressive symptoms. They added: Intranasal mebufotenin benzoate may improve treatment access and convenience, requiring a shorter monitoring period and fewer clinic visits compared with psilocybin and esketamine, respectively. Most patients were cleared for release less than two hours after taking the spray.This latest study was a phase 2b trial to establish safety and efficacy before larger trials. The medicine would need to pass phase 3, the largest phase to gather evidence for regulatory approval before any drug hits the market. The findings come amid a resurgence in new research and investment involving psychedelics, supported in part by evolving political attitudes towards the compounds on federal and state levels.Trump Executive Order Expedites Psychedelic ResearchState governments have shown more interest in the field in recent years, with some funding research into the powerful psychedelic ibogaine. Signs of movement are occurring at the federal level as well. In April, President Donald Trump signed an executive order to expedite research into psychedelics. While first-line treatments for depression are still therapy and traditional antidepressant medications, emerging evidence suggests that fast-acting drugs like mebufotenin could offer a different approach.The compound belongs to the same family as serotonin and is found in the skin, venom and eggs of a few toad species, especially the Sonoran desert toad. AtaiBeckley is seeing the single-dose nasal spray formula through clinical trials. The phase 2b results are promising, but further testing is needed. The company plans to move forward with phase 3 trials.A 2024 study also explored the potential of mebufotenin. This latest trial adds to the growing body of evidence that controlled doses of psychedelic compounds can produce rapid and durable antidepressant effects. The nasal spray could provide some of the same therapeutic effects of other scheduled therapies without the need for healthcare workers to monitor patients for many hours at a time. Treatment-resistant depression affects millions of people worldwide who do not respond to standard treatments.New options are urgently needed. The nasal spray, if approved, could offer a convenient and fast-acting alternative. The trial was double-blind, meaning neither the patients nor the clinical staff knew which dose was given. Clinicians checked on patients at regular intervals to determine if they were safe enough to leave the clinic.The most intense psychedelic effects wore off relatively quickly, regardless of the dose. The study measured depression with a clinical scale from 0 to 60, with higher scores indicating more severe symptoms. After four weeks, the 12 mg group had dropped an average of 11.1 points, the 8 mg group dropped 12.5 points, and the 0.3 mg group dropped 5.5 points. These findings suggest the nasal spray application could provide rapid relief.The researchers concluded that intranasal mebufotenin benzoate was well tolerated and produced rapid, robust, and durable reductions in depressive symptoms. They noted that it may improve treatment access and convenience. The study was published this week. The drug is not without side effects, but most were mild or moderate.The psychedelic experience itself is shorter than with psilocybin, which can last over six hours. This shorter duration could make the treatment more practical for clinics and patients. The development of this nasal spray comes as psychedelic research expands. State governments have shown more interest, and federal attitudes are evolving.AtaiBeckley Plans Next Phase Three TrialsIn April, President Donald Trump signed an executive order to expedite research into psychedelics. This could accelerate the path to approval for drugs like mebufotenin. AtaiBeckley, owned by Eli Lilly, is now in phase 2b. The next step is phase 3, which will involve a larger number of participants.If successful, the drug could reach the market in the coming years. For now, the results offer hope for people with treatment-resistant depression.